USD10
GALT Shares
About Galectin TherapeuticsGalectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
USD10
GALT Shares
About Galectin TherapeuticsGalectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$273.96M
OPEN PRICE
$4.21
LOW (1Y)
$2.03
HIGH (1Y)
$7.13
LOW (24H)
$4.14
HIGH (24H)
$4.42
VOLUME (24H)
$413.76K
25.64%
Price history
Time | Price | Change |
|---|---|---|
Today | $4.21 | |
1 Day | $4.18 | |
1 Week | $3.93 | |
1 Month | $2.74 | |
1 Year | $2.74 |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.